ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
A Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients whose Disease
is resistant or refractory to Tyrosine kinase inhibitors (TKI).